Alexza Pharmaceuticals Inc

Find Ratings Reports
ALXA : : Health Care
$0.94 up 0.02 | 1.63%
Today's Range: 0.91 - 0.95
Avg. Daily Volume: 144,200
06/20/16 - 3:53 PM ET

Financial Analysis


ALEXZA PHARMACTCLS INC's gross profit margin for the first quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ALEXZA PHARMACTCLS INC has very weak liquidity. Currently, the Quick Ratio is 0.07 which clearly shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 43.87% from the same quarter last year. The key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY16 Q1 FY15
Net Sales ($mil)0.720.71
EBITDA ($mil)-4.48-8.49
EBIT ($mil)-5.06-9.37
Net Income ($mil)-3.36-0.4


Balance Sheet Q1 FY16 Q1 FY15
Cash & Equiv. ($mil)4.522.52
Total Assets ($mil)10.5843.17
Total Debt ($mil)67.9564.16
Equity ($mil)-74.34-51.67


Profitability Q1 FY16 Q1 FY15
Gross Profit Margin-622.78-1204.26
EBITDA Margin-622.77-1204.25
Operating Margin-702.08-1328.94
Sales Turnover0.480.09
Return on Assets-229.31-61.15
Return on Equity0.00.0
Debt Q1 FY16 Q1 FY15
Current Ratio0.123.31
Debt/Capital-10.655.14
Interest Expense1.962.23
Interest Coverage-2.58-4.2


Share Data Q1 FY16 Q1 FY15
Shares outstanding (mil)21.7519.42
Div / share0.00.0
EPS-0.16-0.02
Book value / share-3.42-2.66
Institutional Own % n/a n/a
Avg Daily Volume145364.0210637.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ALXA NM Peers 42.37   ALXA NM Peers 27.40

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

ALXA's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

ALXA's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
ALXA NA Peers 15.45   ALXA NA Peers 0.53

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ALXA NM Peers 7.51   ALXA 18.25 Peers -19.42

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ALXA's P/B is negative making this valuation measure meaningless.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

ALXA is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ALXA 3.97 Peers 22.36   ALXA 22.95 Peers 3.12

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ALXA is trading at a significant discount to its industry on this measurement.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

ALXA has a sales growth rate that significantly exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades